News Release

People of East Asian descent have more vessels reclog after endovascular treatment

Stroke: Vascular and Interventional Neurology Journal Report

Peer-Reviewed Publication

American Heart Association

DALLAS, July 12, 2022 — Among people who received endovascular therapy to mechanically remove a clot in their large brain artery, those who had a rare genetic variant found primarily in people of East Asian descent (Japanese, Chinese and Korean) were more likely to have the vessel reclog during or shortly after the procedure, according to a small study published today in Stroke: Vascular and Interventional Neurology, an open access journal jointly published by the American Heart Association/American Stroke Association and the Society of Vascular and Interventional Neurology.

“In the field of acute stroke, genetic testing has not been considered important. However, since our study found that a specific genetic variant substantially affects the outcome of endovascular therapy, physicians involved in acute stroke medicine, especially in East Asian countries and in western countries where many East Asian descendants are living, need to know these findings,” said senior study author Masafumi Ihara, M.D., Ph.D., FAHA, director of neurology at the National Cerebral and Cardiovascular Center in Osaka, Japan.

When blood clots block a large artery supplying blood to the brain, a severe stroke with the potential for serious disability may occur. According to the American Heart Association/American Stroke Association, clot-caused (ischemic) strokes account for 87% of all strokes in the United States.

The genetic variant studied, called RNF213 p.R4810K, is present in 1 in 50 people of East Asian descent and in 80%-90% of people with the genetic disorder moyamoya disease. Moyamoya is a rare, progressive disorder caused by blocked arteries at the base of the brain that can result in a stroke or other neurological symptoms, such as motor or sensory impairment, headache or vertigo. Since moyamoya disease is diagnosed by conventional brain angiography or magnetic resonance angiography (MRA) and symptoms are varied and stroke-related, many people may not know they have moyamoya disease before they have a stroke. In addition to endovascular therapy, bypass surgery is also a treatment option to increase cerebral blood flow. Medically, antiplatelets are used to suppress clot formation in constricted or narrowed arteries.

The researchers analyzed the outcomes of 277 East Asian adults (46.2% women, median age of 76 years) who received endovascular therapy for an ischemic stroke at the National Cerebral and Cardiovascular Center in Osaka, Japan, between 2011 and 2021. All of the patients had an acute anterior-circulation large vessel occlusion, a stroke in which a clot blocks one of the large arteries responsible for supplying blood to the forebrain (the forebrain is the largest of three parts of the brain and includes the cerebrum, thalamus, hypothalamus, pituitary gland, limbic system, and the olfactory bulb; it is responsible for processing complex brain and physical activities, numerous sensory functions and voluntary motor activities).

Several types of endovascular procedures are available to restore blood flow to the artery, such as removing the blood clots through a stent retriever device or suction device, or opening the clogged vessel by inflating a balloon in the area and installing a stent to hold the blood vessel open. The type of procedure performed was determined by the medical team and was unrelated to whether the patient had the genetic variant.

Researchers compared 10 patients found to carry the RNF213 p.R4810K variant to 267 patients without the variant on several short-term outcome measures. The results were adjusted for the age of the patients.

While people with the genetic variant were just as likely as non-carriers to initially have success with reestablishing blood flow to at least half of the brain tissue that had been deprived of blood during the stroke, outcomes revealed:

  • People with the genetic variant were far more likely (70%) than non-carriers (5.6%) to have the treated artery become re-blocked before the procedure was complete, called instant reocclusion.
  • People with the genetic variant were far more likely (60%) than non-carriers (0.4%) to have the treated artery become re-blocked within two weeks of an initially successful endovascular procedure, called early reocclusion.

“We did not imagine this genotype would affect the outcome of endovascular therapy so substantially,” Ihara said. “Information on the genotype will be useful for people who receive endovascular therapy (hopefully before the procedure) because individuals who are of East Asian descent and have the genetic variant need to be more strictly monitored than usual for reocclusion during and after endovascular treatment.”

The number of people found to have the genetic variant was too small to determine which clot-removal devices or medicines may be better at preventing reocclusion. The researchers are initiating a larger, multi-center study to answer these questions, and to examine the long-term outcome of variant carriers following endovascular therapy. “It’s important to note, however, that genotyping is currently only available in a research setting, for participants in a clinical trial such as ours,” Ihara said.

Results from this study involving an East Asian population may not be generalized to other people with different genetic backgrounds. “However, additional genetic variants may affect the outcome of endovascular therapy in different ethnic populations, which needs further investigation,” Ihara said.

In addition to stroke, the RNF213 p.R4810K gene has previously been associated with high blood pressurepulmonary high blood pressureheart attack and the narrowing of abdominal blood vessels.

Co-authors are Takeshi Yoshimoto, M.D.; Kanta Tanaka, M.D., Ph.D.; Junpei Koge, M.D.; Satoshi Saito, M.D., Ph.D.; Hiroshi Yamagami, M.D., Ph.D.; Yuriko Nakaoku, M.D., Ph.D.; Soshiro Ogata, M.D., Ph.D.; Kunihiro Nishimura, M.D., Ph.D.; Eriko Yamaguchi, M.D.; Tetsuya Chiba, M.D.; Daisuke Kawakami, M.M.Sc.; Masayuki Shiozawa, M.D.; Naruhiko Kamogawa, M.D.; Tsuyoshi Ohta, M.D., Ph.D.; Tetsu Satow, M.D., Ph.D.; Manabu Inoue, M.D., Ph.D.; Yorito Hattori, M.D., Ph.D.; Kazuo Washida, M.D., Ph.D.; Hiroharu Kataoka, M.D., Ph.D.; Jong-Won Chung, M.D., Ph.D.; Oh Young Bang, M.D., Ph.D.; Kazunori Toyoda, M.D., Ph.D.; Masatoshi Koga, M.D., Ph.D.; and Hirofumi Maruyama, M.D., Ph.D. Authors’ disclosures are listed in the manuscript.

The study was supported by the Japan Agency for Medical Research and Development (AMED), the Japanese Society for Neurovascular Therapy, the SENSHIN Medical Research Foundation and the National Center Biobank Network/NCVC Biobank Resource.

Studies published in the American Heart Association’s scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.orgFacebookTwitter or by calling 1-800-AHA-USA1.

About the Society of Vascular and Interventional Neurology

The Society of Vascular and Interventional Neurology was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. Our mission is to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases. For further information about SVIN, please visit or find us on FacebookTwitter or LinkedIn.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.